Insider · CIK 0002034523
Warner Weston Biddle
Files at KYTX (Kyverna Therapeutics, Inc.). First filing -, latest -.
In brief
Warner Weston Biddle files SEC Form 4 as CEO and director at KYTX (Kyverna Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Warner Weston Biddle has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | KYTX Kyverna Therapeutics, Inc. | AGrant or award Common Stock | +58,000 | $0.00 | $0 | 58,000 | Mar 17, 2026 |
| Mar 13, 2026 | KYTX Kyverna Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +350,000 | $0.00 | $0 | 350,000 | Mar 17, 2026 |
| Apr 11, 2024 | KYTX Kyverna Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +332,500 | $0.00 | $0 | 332,500 | Apr 15, 2025 |
Questions about Warner Weston Biddle
Answered from the filings on this page, as of the latest one.
Is Warner Weston Biddle buying or selling?
Warner Weston Biddle has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Warner Weston Biddle's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Warner Weston Biddle has 0.
Where does Warner Weston Biddle file Form 4?
Warner Weston Biddle has filed Form 4 at KYTX (Kyverna Therapeutics, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.